Terns Pharmaceuticals (TERN) Enterprise Value (2020 - 2023)
Terns Pharmaceuticals' Enterprise Value history spans 4 years, with the latest figure at -$266.6 million for Q3 2023.
- For Q3 2023, Enterprise Value fell 42.35% year-over-year to -$266.6 million; the TTM value through Sep 2023 reached -$266.6 million, down 42.35%, while the annual FY2022 figure was -$283.1 million, 70.57% down from the prior year.
- Enterprise Value reached -$266.6 million in Q3 2023 per TERN's latest filing, up from -$285.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$11.7 million in Q1 2020 to a low of -$285.6 million in Q2 2023.
- Average Enterprise Value over 4 years is -$162.7 million, with a median of -$177.2 million recorded in 2021.
- Peak YoY movement for Enterprise Value: plummeted 1572.2% in 2021, then increased 24.46% in 2022.
- A 4-year view of Enterprise Value shows it stood at -$74.9 million in 2020, then tumbled by 121.74% to -$166.0 million in 2021, then tumbled by 70.57% to -$283.1 million in 2022, then grew by 5.83% to -$266.6 million in 2023.
- Per Business Quant, the three most recent readings for TERN's Enterprise Value are -$266.6 million (Q3 2023), -$285.6 million (Q2 2023), and -$282.6 million (Q1 2023).